Purpose: The aim of this study was to assess the efficacy and safety of bevacizumab in the treatment of pterygium and to mainly explore its effects on recurrence rate and complications.
Results: A total of 474 patients with 482 eyes in 9 randomized controlled trials were analyzed. The pooled estimate showed that bevacizumab had no statistically significant effect on preventing pterygium recurrence [RR 0.90, 95% confidence interval (CI) 0.77-1.07, P = 0.23]. None of the subgroup analyses yielded significant results in favor of bevacizumab (surgery group: RR 0.77, 95% CI 0.50-1.18, P = 0.23; nonsurgery group: RR 0.98, 95% CI 0.86-1.11, P = 0.76; primary pterygium group: RR 0.82, 95% CI 0.53-1.26, P = 0.36; recurrent pterygium group: RR 0.95, 95% CI 0.82-1.09, P = 0.44). There were no statistically significant differences in the complications between the 2 groups (RR 1.00, 95% CI 0.73-1.37, P = 1.00). However, the bevacizumab group was associated with a higher risk of developing subconjunctival hemorrhage (RR 3.34, 95% CI 1.07-10.43, P = 0.04).
Conclusions: Topical or subconjunctival bevacizumab was relatively safe and well tolerated, but it had no statistically significant effect on preventing pterygium recurrence. A large-scale trial with a suitable dosage and a longer follow-up would be required to rule out the possibility of any treatment benefit.
Key Words: bevacizumab, pterygium, meta-analysis (Cornea 2014;33:154-160) P terygium is a very common degenerative condition of the conjunctiva, usually appearing in the form of a triangular fleshy fibrovascular tissue proliferation from the bulbar conjunctiva onto the cornea. Pterygium can cause chronic conjunctival hyperemia, corneal astigmatism, corneal dellen, and impairment of vision. 1, 2 The main goal of the treatment of pterygium is to prevent recurrence. Despite the availability of a wide variety of surgical techniques and adjunct drugs, the recurrence rate varies highly from 50% to 80% for simple excision to 5% to 15% for more advanced techniques. 3 Several studies [4] [5] [6] [7] [8] have evaluated the efficacy of adjunctive therapies, such as b-radiation, mitomycin C, and 5-fluorouracil, combined with simple excision to reduce the recurrence rate. Although these routine antifibrotic medications are associated with good results in modulating wound healing in pterygium surgery, they carry with them the possibility for significant morbidity as a result of adverse effects. 9 The treatment of pterygium is still quite controversial.
Recently, the role of inflammation and fibrovascular proliferation has been particularly highlighted as important factors in the pathogenesis of pterygia. Many studies [10] [11] [12] have shown vascular endothelial growth factor (VEGF) to be increased in the pathogenesis of pterygia. Bevacizumab (Avastin, Genentech, South San Francisco, CA) is a recombinant, humanized anti-VEGF antibody that binds all VEGF isoforms and exerts a neutralizing effect by inhibiting the VEGF-receptor interaction. 9, 13 Although the numbers are still relatively small, evidence suggests that bevacizumab may be effective in the treatment of corneal and iris neovascularization. However, its effect on primary and recurrent pterygium is more controversial. 14 Although many randomized controlled trials (RCTs) reported to date have shown varying results in the efficacy and safety of bevacizumab in the treatment of pterygium, the results are not completely consistent. Moreover, the conclusion of a single RCT is limited by many factors such as the small size, different population, follow-up period, and surgery technique. Therefore, we performed this meta-analysis to evaluate the efficacy and safety of bevacizumab in the treatment of pterygium.
MATERIALS AND METHODS

Search and Selection Strategy
Two reviewers (Q.W. and Y.B.) independently searched the MEDLINE, EMBASE, Web of Science, and Cochrane Central Register up to July 10, 2013. To maximize the data search, the search strategy used relevant keywords and medical subject heading (MeSH) terms including "bevacizumab and pterygium" or "avastin and pterygium." We also hand searched the reference lists of retrieved articles, case reports for relevant articles. We did not apply any language restrictions.
Inclusion Criteria
Two reviewers independently screened the titles and abstracts of studies to identify those that fulfilled the inclusion criteria: (1) RCT; (2) patients with pterygium, including the spectrum of primary pterygium, recurrent pterygium, and impending recurrent pterygium; (3) subconjunctival or topical application of bevacizumab, with or without surgery; (4) comparison of bevacizumab with control; and (5) at least 1 of the following outcomes: quantified recurrences and quantified complications (recurrence rate and complications). We included published and unpublished studies without language restriction. No limits on the dose of bevacizumab or length of follow-up were set.
Data Extraction and Quality Assessment
Three reviewers (Q.W., Y.B., and X.N.) independently performed the data extraction that met the inclusion criteria. The titles and abstracts were scanned to exclude any clearly irrelevant studies. The full texts of the remaining articles were read to determine whether they contained information on the useful topic. Any disagreement was resolved by discussion to reach a consensus among the investigators. The following data were collected from each study: (1) publication data: the first author's last name, year of publication, country of origin; (2) characteristics of the study population: sample size, gender, age, and diagnoses; (3) treatment: surgery, dose of bevacizumab, and administration route; (4) follow-up period; (5) endpoint measurement: the number of recurrences, complications, and subconjunctival hemorrhages.
Three reviewers (Q.W., Y.B., and X.N.) independently evaluated the study design of each publication and the risk of bias involving selection bias, performance bias, detection bias, and attrition bias using elements of the Cochrane collaboration tool. 15 The methodological quality of the included RCTs was assessed by using the Jadad scale, which included randomization, blinding, description of withdrawals, and dropouts. The quality scale ranges from 0 to 5 points, with a score of #2 qualifying as a low-quality study and a score of $3 as a high-quality study. 16 
Outcome Measurement and Relevant Definition
There were 2 main outcome measurements in this metaanalysis. (1) Recurrence rate: the outcome of pterygium excision can be classified into 4 grades: grade 1, the conjunctiva has a normal appearance with no signs of recurrence; grade 2, only fine episcleral vessels are present at the surgical site without any fibrous tissue; grade 3, fibrovascular tissue is present in the excised area, reaching the limbus but not invading the cornea (impending recurrent pterygium); and grade 4, corneal recurrence with fibrovascular tissue covering the excision area and invading the cornea (true recurrence). 17 Among the 7 studies that reported recurrences, the outcome was defined as grade 4 in 6 studies 18-23 and as grade 3 or above in 1 study. 24 The number of recurrences was calculated at the end of the follow-up in each study. (2) Complications (including frequent complications and serious complications): frequent complications (inflammation, photophobia, lacrimation, conjunctival erythema, subconjunctival hemorrhage, conjunctival flap edema, and autoconjunctival graft loss, etc.) were defined as those that were not clinically significant and resolved spontaneously or on using conservative measures, no matter whether moderate or severe (subconjunctival hemorrhage was observed in
Statistical Analyses
Statistical analyses were performed using RevMan 5.0 (The Cochrane Collaboration, Copenhagen, Denmark) and STATA software 12.0 (StataCorp, College Station, TX). The recurrence rate and complications were treated as dichotomous variables. Dichotomous data were presented as the relative risk (RR) with a 95% confidence interval (CI). We assessed for the heterogeneity between studies by calculating a Cochran Q statistic and an I 2 statistic. 27 If significant heterogeneity (I 2 . 50%) was observed between studies, a random-effects model was used to pool the data; otherwise, a fixed-effects model was used. Sensitivity analysis and subgroup analysis for the primary outcome measurement of recurrence rate were performed in a predefined manner to assess the impact of the following: (1) treatment method (nonsurgery); (2) diagnoses (recurrent pterygium and impending recurrent pterygium); (3) follow-up (follow-up time #6 months); (4) administration route (topical eye drop); and (5) methodological quality (Jadad score #2). Meta-regression analyses considered the administered bevacizumab dose (continuous variable). To detect publication bias, we visually examined funnel plots per assessed outcome and further assessed asymmetry by using Egger and Begg tests. All P values were 2-tailed, and a P value ,0.05 was considered statistically significant. Figure 1 is a flow diagram of the selection of eligible studies. Forty-seven records were identified by the primary literature search. However, after screening the titles and abstracts, 24 irrelevant studies were excluded. We therefore retrieved 23 potentially relevant articles for a detailed review. Of these studies, 1 abstract, 4 review articles, 5 case reports, and 4 noncontrolled studies were further excluded. Consequently, the remaining 9 RCTs were included for the metaanalysis (Fig. 1) .
RESULTS
Studies Selection
Study Characteristics
A total of 474 patients with 482 eyes in 9 included studies were enrolled in this meta-analysis. The baseline characteristics of the included studies are summarized as follows: sample sizes (range, 30-80 eyes); country; mean age (range, 41-59 years); diagnoses; treatment method; follow-up (range, 1-12 months) (see Table, Supplemental Digital Content 1, http://links.lww.com/ICO/A186). Dose regimen and outcome measurements are summarized as follows: total dose of bevacizumab (range, 1.25-7.5 mg); administration route; other medications; recurrences; complications (no serious complications were observed in all the included studies); subconjunctival hemorrhages (see Table, Supplemental Digital Content 2, http://links.lww.com/ICO/A187). The study design of each publication and the risk of bias are described in detail. The Jadad score of the 9 included studies was acceptable: a score of 4 for 1 trial, a score of 3 for 6 trials, and a score of 2 for 2 trials (Table 1) .
Meta-analysis
The outcome measurements of this meta-analysis are summarized in Figures 2 and 3 . Seven studies reported recurrences. The pooled estimate showed that bevacizumab had no statistically significant effect on the prevention of pterygium recurrence (RR 0.90, 95% CI 0.77-1.07, P = 0.23; P heterogeneity = 0.05, I 2 = 52%) (Fig. 2) . The source of this significant heterogeneity among the included studies was found in the subgroup analysis for the surgery group [18] [19] [20] [21] 24 and for the nonsurgery group, 22, 23 but it showed that there was no significant beneficial effect of bevacizumab: surgery group (RR 0.77, 95% CI 0.50-1.18, P = 0.23; P heterogeneity = 0.39, I 2 = 3%); nonsurgery group (RR 0.98, 95% CI 0.86-1.11, P = 0.76; P heterogeneity = 0.57, I 2 = 0%) ( Fig. 2A) . Similarly, the subgroup analysis for the primary pterygium group 18, 19, 21, 24 and recurrent pterygium group 20, 22, 23 showed that there was no significant beneficial effect of bevacizumab: primary pterygium group (RR 0.82, 95% CI 0.53-1.26, P = 0.36; P heterogeneity = 0.34, I 2 = 10%); recurrent pterygium group (RR 0.95, 95% CI 0.82-1.09, P = 0.44; P heterogeneity = 0.20, I 2 = 38%) ( Fig. 2B) . None of other subgroup analyses yielded significant results in favor of bevacizumab (data not shown). Meta-regression demonstrated that there was no positive correlation between the dose and the effect of bevacizumab on the prevention of pterygium recurrence (P = 0.490).
Eight studies reported that complications were analyzed for RR. There was no significant heterogeneity among the studies (P heterogeneity = 0.25, I 2 = 23%); thus, a fixed-effects model was used to pool the data. This showed no statistically significant differences in complications between the bevacizumab group and the control group (RR 1.00, 95% CI 0.73-1.37, P = 1.00; Fig. 3A ). However, the bevacizumab group was associated with a higher risk of subconjunctival hemorrhage developing as compared with that in the control group (RR 3.34, 95% CI 1.07-10.43, P = 0.04; P heterogeneity = 0.27, I 2 = 24%; Fig. 3B ).
Publication bias was examined by evaluating funnel plots for recurrence rate and complications. Egger and Begg tests showed that no potential publication bias existed among the included trials for the 2 end points analyzed (Egger test P = 0.464, Begg test P = 0.260 for recurrence rate; Egger test P = 0.061, Begg test P = 0.133 for complications) (Fig. 4 ).
DISCUSSION
Our study is the first meta-analysis ever published on this topic. Seven studies in this meta-analysis reported recurrences. Regretfully, it showed that there was no significant beneficial effect of bevacizumab. The most common endpoint determined by scientific studies is the recurrence of pterygium, which is usually defined as a corneal recurrence (grade 4). 28 Among the 7 studies, only 1 study 24 defined pterygium recurrence as being grade 3 or above, which was different from that in the other 6 studies that defined this as grade 4, but this might have an impact on the result.
There were 3 different diagnoses including primary pterygium, 18, 19, 21, [24] [25] [26] recurrent pterygium, 20 and impending recurrent pterygium 22, 23 in the included studies. Impending recurrent pterygium is more likely to progress to a true recurrence, and a recurrent pterygium is often more troublesome, tends to have a more exuberant fibrovascular growth response, and causes more surgical difficulty than does primary pterygium. 22 Among the 7 studies that reported recurrences, only 1 study 21 in just the primary pterygium group reported a significant beneficial effect of bevacizumab. Nevertheless, the studies 22, 23 in the recurrent pterygium group only found that topical or subconjunctival bevacizumab might be partially and transiently delaying the recurrence of impending recurrent pterygium but was not effective in preventing absolute recurrence.
Ideal dose and treatment regimen should be important factors for the effects of bevacizumab on pterygium. The effects of anti-VEGF agents are often transient owing to the short half-life of the drug, and treatment often needs to be repeated [29] [30] [31] ; therefore, how to achieve a minimal effective dose and a maximum safe dose turned out to be the key and difficult problem. In the 9 studies included, Nava-Castañeda et al 21 reported a significant beneficial effect (P = 0.04) of bevacizumab on preventing pterygium recurrence with a total of 2.5 or 5 mg of subconjunctival bevacizumab. Banifatemi et al 25 reported no adverse effects on early postoperative wound healing of excised primary pterygium that was observed in patients who received a total of 7.5 mg of subconjunctival bevacizumab. In addition, pterygium recurrence after surgical treatment is usually seen within 6 months in most cases, but sometimes, this occurs later, so a 12-month follow-up period is recommended. 32 Among the 7 studies that reported recurrences, 1 study 20 reported that there was no significant effect of bevacizumab on preventing pterygium recurrence (P = 0.244), but there was a significant effect on preventing corneal neovascularization (P = 0.024) with a 6-month follow-up, which might have a significant result for a longer follow-up duration.
Complications include frequent complications and serious complications. No serious complications were observed in all the included studies, and there were no statistically significant differences in frequent complications between the bevacizumab group and the control group, showing the safety and good tolerance of bevacizumab. However, the pooled data (RR) showed that the bevacizumab group was associated with a higher risk of developing subconjunctival hemorrhage (P = 0.04). Although all the subconjunctival hemorrhages were resolved within 2 weeks with no other consequences, 26 the result must be further demonstrated as a result of the small sample size and the huge differences in the number of subconjunctival hemorrhages between the 2 groups in 1 study, 26 in which subconjunctival hemorrhages in the bevacizumab group were much more than in the control group, and this might be explained by the different administration routes between the 2 groups (subconjunctival injection in the bevacizumab group and topical eye drops in the control group).
It is necessary to mention the relatively limited power of our meta-analysis to find a treatment benefit. For example, the country zones of the 9 studies included are relatively circumscribed (6 18,19,22,23,25,26 in Asia, 1 each 20,21 in Africa and North-America). The quality of these studies needs to be improved (2 low-quality studies 18, 23 with a score of 2). Other drawbacks pertinent to this meta-analysis were the differences in the characteristics among included studies, encompassing population characteristics (age, gender, race), dosage regimen, follow-up duration, sample size, etc. It is worth noting that only 474 patients with 482 eyes were involved in the 9 RCTs, which might have masked the true results.
In summary, this meta-analysis found that topical or subconjunctival bevacizumab is relatively safe and well tolerated, but it had no significant effect on preventing pterygium recurrence. In the future, further investigations in prospective randomized controlled studies incorporating a large population and long-term follow-up would be necessary to rule out the possibility of any treatment benefit.
